Market Trends of Hepatitis Therapeutics Industry
This section covers the major market trends shaping the Hepatitis Therapeutics Market according to our research experts:
Hepatitis C Segment is Expected to Hold a Major Market Share in the Hepatitis Therapeutics Market
Hepatitis C is a liver disease caused by the hepatitis C virus. Hepatitis C can range in severity from mild to fatal.Acute hepatitis C occurs within the first six months after exposure to the hepatitis C virus, and chronic hepatitis C can develop into lifelong hepatitis C if left untreated. According to data published by the World Health Organization (WHO) in July 2021, an estimated 58 million people have chronic hepatitis C virus, and about 1.5 million new infections occur annually. According to the same source, the hepatitis C virus is a blood-borne pathogen, and the most common form of infection is exposure to small amounts of blood. This often happens with unsafe injections and unsafe health care.
The hepatitis C segment is anticipated to witness growth in the hepatitis therapeutics market due to the rise in hepatitis infection globally. For instance, as per the ECDC 2022 report, 26 cases of hepatitis of unknown etiology were reported in May 2022 in Spain. Moreover, it is expected to show a similar trend over the forecast period due to the high prevalence of hepatitis C in developing and developed regions, as well as the growing availability of effective drugs in the market. In addition, the introduction of several products by major players is expected to boost the segment's growth. For example, in June 2021, Gilead Sciences, Inc. received approval from the FDA for Epclusa (sofosbuvir/velpatasvir) for the treatment of chronic hepatitis C virus (HCV) in children under 3 years of age, regardless of the HCV genotype or severity of the liver disease. Furthermore, the rise in clinical studies related to hepatitis C is anticipated to drive market growth. For instance, in February 2022, the Task Force for Global Health sponsored a clinical trial to assess the outcomes of hepatitis C-affected mother-infant pairs exposed to direct-acting antivirals (DAAs) during pregnancy within a global clinical case registry.
Therefore, due to the rise in the prevalence of hepatitis and the increase in product launches and clinical studies associated with the treatment of hepatitis C, the segment is anticipated to witness growth in the market over the forecast period.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
Due to an increase in hepatitis infections and an increase in the commercial availability of hepatitis drugs in the region, North America is expected to hold a significant market share in the hepatitis therapeutics market. For example, between April and September 2022, PHAC looked into 28 cases of acute severe hepatitis in children in Canada that met the national case definition.
Moreover, the data published in the report Viral Hepatitis National Strategic Plan: 2021-2025 for the United States stated that the goal of the strategic plan is to improve viral hepatitis-related health outcomes of people with viral hepatitis, reduce viral hepatitis-related disparities and health inequities, and improve viral hepatitis surveillance and data usage, etc. In addition, favorable reimbursement policies, high rates of improved access to healthcare, and the availability of well-functioning healthcare infrastructure also stimulate growth across the regional market on a large scale.
Furthermore, the presence of key market players, coupled with growing awareness programmes and the introduction of the latest products in the region, is responsible for bolstering the market's growth in the United States. For instance, in December 2021, the United States Food and Drug Administration approved Pre Hebrio [a recombinant vaccine] to prevent infections caused by all known minor hepatitis B virus (HBV) infections in adults. However, a national strategic plan was launched by the United States Department of Health and Human Services in January 2021 to eradicate hepatitis. It included five main goals, objectives and strategies to achieve these goals, and indicators with measurable objectives for monitoring progress. Therefore, the introduction of such programmes by the government will improve the treatment of hepatitis in the country.
Thus, due to the rise in the prevalence of hepatitis, the increase in government initiatives and strategic plans for hepatitis, and the surge in product launches, it is anticipated that North America will witness growth in the market over the forecast period.
